INTERFERON ALFA-2B

Summary

Interferon Alfa-2B (CHEMBL1201558) is an approved protein (ATC L03AB05); indicated across 38 conditions including neoplasm and chronic hepatitis c virus infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L03AB05
• Indications: 38 conditions
• Clinical trials: 30

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201558
Name	INTERFERON ALFA-2B
Type	Protein
Max phase	4
ATC	L03AB05

Also known as: Interferon alfa-2b, Intron a, Intron a hsa-free, Intron-a, Introna, Locteron, SCH 30500, SCH-30500, SCH30500, Viraferon, INTERFERON ALFA-2B, INTERFERON-ALFA2B

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

14 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
chronic hepatitis C virus infection	4	MONDO:0005354	EFO:0004220
cutaneous melanoma	4	MONDO:0005012	EFO:0000389
melanoma	4	MONDO:0005105	EFO:0000756
chronic myeloid leukemia	4	MONDO:0011996	EFO:0000339
plasma cell myeloma	4	MONDO:0009693	EFO:0001378
hepatitis B virus infection	4	MONDO:0005344	EFO:0004197
chronic hepatitis B virus infection	4	MONDO:0005366	EFO:0004239
Kaposi’s sarcoma	4	MONDO:0005055	EFO:0000558
anogenital human papillomavirus infection	4	MONDO:0005647	EFO:0007147
hairy cell leukemia	4	MONDO:0018935	EFO:1000956
follicular lymphoma	4	MONDO:0018906	MONDO:0018906
carcinoid tumor	4	MONDO:0005369	MONDO:0024503
blast phase chronic myelogenous leukemia, BCR-ABL1 positive	4	MONDO:0006115	EFO:1000131

16 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hepatitis C virus infection	3	MONDO:0005231	EFO:0003047
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
HIV infectious disease	3	MONDO:0005109	EFO:0000764
cirrhosis of liver	3	MONDO:0005155	EFO:0001422
clear cell renal carcinoma	2	MONDO:0005005	EFO:0000349
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
prostate adenocarcinoma	2	MONDO:0005082	EFO:0000673
kidney cancer	2	MONDO:0002367	MONDO:0002367
human papilloma virus infection	2	MONDO:0005161	EFO:0001668
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
leukemia	1	MONDO:0005059	EFO:0000565
breast neoplasm	1	MONDO:0021100	EFO:0003869
breast carcinoma in situ	1	MONDO:0004658	MONDO:0004658
ovarian cancer	1	MONDO:0008170	MONDO:0008170
hematopoietic and lymphoid system neoplasm	1	MONDO:0002334	MONDO:0044881

8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 30.

Phase distribution

Phase	Trials
PHASE2	7
PHASE1	6
PHASE4	4
PHASE3	4
PHASE2/PHASE3	4
PHASE1/PHASE2	3
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00854581	PHASE4	TERMINATED	Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
NCT02199327	PHASE4	COMPLETED	Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia
NCT02323659	PHASE4	TERMINATED	Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
NCT02360592	PHASE4	COMPLETED	Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients
NCT00003641	PHASE3	ACTIVE_NOT_RECRUITING	High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
NCT00125814	PHASE3	TERMINATED	Structured Treatment Interruptions With or Without Pegylated Interferon Alpha for HIV-Infected Patients After Prolonged Viral Suppression
NCT00221702	PHASE3	COMPLETED	PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)
NCT00624325	PHASE2/PHASE3	COMPLETED	Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders
NCT01359956	PHASE3	COMPLETED	Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma
NCT03537274	PHASE2/PHASE3	COMPLETED	Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)
NCT03547154	PHASE2/PHASE3	TERMINATED	Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)
NCT03552549	PHASE2/PHASE3	TERMINATED	SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
NCT00001114	PHASE2	COMPLETED	The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi’s Sarcoma
NCT00505635	PHASE2	TERMINATED	Biochemotherapy With Temozolomide for Metastatic Melanoma
NCT00561912	PHASE2	TERMINATED	Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
NCT00613509	PHASE2	TERMINATED	Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
NCT00919633	PHASE2	COMPLETED	Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C
NCT00963664	PHASE2	WITHDRAWN	Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
NCT01274273	PHASE2	UNKNOWN	Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
NCT01639885	PHASE1/PHASE2	COMPLETED	Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer
NCT02151448	PHASE1/PHASE2	COMPLETED	αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
NCT02568241	PHASE1/PHASE2	UNKNOWN	Interferon-α After DLI for the Prevention of Relapse
NCT00000694	PHASE1	COMPLETED	A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi’s Sarcoma
NCT00001035	PHASE1	COMPLETED	The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections
NCT01217359	PHASE1	COMPLETED	Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling
NCT01409174	PHASE1	TERMINATED	IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
NCT01462773	PHASE1	COMPLETED	Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
NCT02174172	PHASE1	COMPLETED	A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
NCT00002270	Not specified	COMPLETED	A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection
NCT02185261	Not specified	UNKNOWN	Interferon α for the Therapy of Minimal Residual Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).